Flamel Technologies SA (FLML) Rating Reiterated by JMP Securities
Flamel Technologies SA (NASDAQ:FLML)‘s stock had its “outperform” rating restated by analysts at JMP Securities in a report released on Wednesday. They presently have a $16.00 price target on the stock. JMP Securities’ target price indicates a potential upside of 32.78% from the stock’s previous close.
Several other equities analysts also recently weighed in on the company. Leerink Swann reissued an “outperform” rating and set a $16.00 target price on shares of Flamel Technologies SA in a research report on Tuesday. Zacks Investment Research upgraded Flamel Technologies SA from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $18.63.
Flamel Technologies SA (NASDAQ:FLML) opened at 12.05 on Wednesday. Flamel Technologies SA has a one year low of $7.56 and a one year high of $19.78. The company has a market capitalization of $496.95 million, a P/E ratio of 29.18 and a beta of 1.42. The stock’s 50 day moving average price is $13.71 and its 200 day moving average price is $11.76.
Flamel Technologies SA (NASDAQ:FLML) last released its earnings results on Monday, August 8th. The company reported ($0.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by $0.08. The company had revenue of $38.90 million for the quarter, compared to the consensus estimate of $32.80 million. Flamel Technologies SA had a net margin of 12.11% and a return on equity of 25.19%. The business’s revenue for the quarter was down 20.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.34 EPS. Equities analysts anticipate that Flamel Technologies SA will post ($1.08) EPS for the current fiscal year.
In other news, Director Craig R. Stapleton bought 10,000 shares of the stock in a transaction on Thursday, September 1st. The stock was acquired at an average cost of $13.52 per share, for a total transaction of $135,200.00. Following the acquisition, the director now owns 519,678 shares of the company’s stock, valued at $7,026,046.56. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Michael S. Anderson bought 5,000 shares of the stock in a transaction on Monday, August 22nd. The stock was purchased at an average price of $14.30 per share, with a total value of $71,500.00. The disclosure for this purchase can be found here. 4.45% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of the company. Brown Capital Management LLC boosted its stake in shares of Flamel Technologies SA by 36.5% in the second quarter. Brown Capital Management LLC now owns 790,206 shares of the company’s stock valued at $8,487,000 after buying an additional 211,392 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Flamel Technologies SA during the second quarter valued at $210,000. Emerald Acquisition Ltd. purchased a new stake in shares of Flamel Technologies SA during the second quarter valued at $6,530,000. Wall Street Access Asset Management LLC boosted its stake in shares of Flamel Technologies SA by 30.4% in the second quarter. Wall Street Access Asset Management LLC now owns 187,650 shares of the company’s stock valued at $2,015,000 after buying an additional 43,750 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its stake in shares of Flamel Technologies SA by 62.8% in the second quarter. State of New Jersey Common Pension Fund D now owns 32,915 shares of the company’s stock valued at $354,000 after buying an additional 12,695 shares in the last quarter. Institutional investors and hedge funds own 70.33% of the company’s stock.
About Flamel Technologies SA
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Stock Ratings for Flamel Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies SA and related stocks with our FREE daily email newsletter.